Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic...
Clinical Trial
Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced...
General Oncology Announces Formation of Scientific Advisory Board
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for...
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis
Pediatric dosing expected to begin in Q4 2025 Pivotal cohort expected to begin enrolling in Q1 2026 BLA submission anticipated...
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients...
SEED Therapeutics Completes $30 Million Series A-3 Financing
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational...
BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief AI Officer
Slava Akmaev, Ph.D. BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief...
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025
Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under...
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - September...
AI in Oncology For Analytical Solutions Market Size & Share to Surpass $8.86 Billion by 2035, Growing at a CAGR 21% | Vantage Market Research
Global AI in Oncology For Analytical Solutions Market to Transform Cancer Care Accelerating Early Detection, Precision Treatment, and Patient Outcomes....
Hemogenyx Pharmaceuticals PLC Signs Letter of Intent
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in EstoniaFirst Potential Near-Term...
Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
VANCOUVER, BC / ACCESS Newswire / September 22, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")...
Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis
BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 22, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European pharmaceutical company focused on...
The Digital Medicine Society Unveils Healthcare 2030 — A Blueprint to Transform U.S. Healthcare in the Digital Era
Launch coincides with the Healthcare 2030 Summit in Washington, DC, bringing together top government officials, industry leaders, and patient advocates...
BYOD or Bust: Are Clinical Trials Ready for the Device Revolution? Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into the current landscape of "Bring Your Own Device" (BYOD) adoption across therapeutic areas...
Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into patterns in the current use of clinical outcome assessment (COA) and digital health...
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with...
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of...